Next Article in Journal
miR-24 Targets the Transmembrane Glycoprotein Neuropilin-1 in Human Brain Microvascular Endothelial Cells
Next Article in Special Issue
Global Analysis of RNA-Dependent RNA Polymerase-Dependent Small RNAs Reveals New Substrates and Functions for These Proteins and SGS3 in Arabidopsis
Previous Article in Journal
Acknowledgment to Reviewers of Non-Coding RNA in 2020
Previous Article in Special Issue
Exosomes in Immune Regulation
Review

MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease

1
Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Lifespan Academic Medical Center, The Warren Alpert Medical School of Brown University, Providence, RI 02903, USA
2
Department of Pathology and Laboratory Medicine, Boston University School of Medicine, 670 Albany Street, Boston, MA 02118, USA
3
German Center for Neurodegenerative Diseases, Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, 37075 Göttingen, Germany
*
Author to whom correspondence should be addressed.
Received: 30 November 2020 / Revised: 14 January 2021 / Accepted: 28 January 2021 / Published: 1 February 2021
(This article belongs to the Collection Feature Papers in Non-coding RNA)
The neurological damage of Alzheimer’s disease (AD) is thought to be irreversible upon onset of dementia-like symptoms, as it takes years to decades for occult pathologic changes to become symptomatic. It is thus necessary to identify individuals at risk for the development of the disease before symptoms manifest in order to provide early intervention. Surrogate markers are critical for early disease detection, stratification of patients in clinical trials, prediction of disease progression, evaluation of response to treatment, and also insight into pathomechanisms. Here, we review the evidence for a number of microRNAs that may serve as biomarkers with possible mechanistic insights into the AD pathophysiologic processes, years before the clinical manifestation of the disease. View Full-Text
Keywords: plasma microRNAome; MCI; epigenetic dysregulation plasma microRNAome; MCI; epigenetic dysregulation
Show Figures

Figure 1

MDPI and ACS Style

Kanach, C.; Blusztajn, J.K.; Fischer, A.; Delalle, I. MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease. Non-Coding RNA 2021, 7, 8. https://0-doi-org.brum.beds.ac.uk/10.3390/ncrna7010008

AMA Style

Kanach C, Blusztajn JK, Fischer A, Delalle I. MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease. Non-Coding RNA. 2021; 7(1):8. https://0-doi-org.brum.beds.ac.uk/10.3390/ncrna7010008

Chicago/Turabian Style

Kanach, Colin, Jan K. Blusztajn, Andre Fischer, and Ivana Delalle. 2021. "MicroRNAs as Candidate Biomarkers for Alzheimer’s Disease" Non-Coding RNA 7, no. 1: 8. https://0-doi-org.brum.beds.ac.uk/10.3390/ncrna7010008

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop